This is a Phase I study evaluating the safety and feasibility of lentiviral transduced huCART-meso cells when given in combination with VCN-01 in a 3+3 dose (de)escalation design as follows:
Cohort 1 (N = 3-6): will receive VCN-01 as a single IV infusion of 3.3×1012 vp on Day 0, followed by a single dose of 5×107 huCART-meso cells on Day 14 via IV infusion. This cohort will be evaluated as follows:
If 1 DLT/3 subjects occurs, Cohort 1 will be expanded to enroll an additional 3 evaluable subjects.
If 0 DLT/3 subjects or 1 DLT/6 subjects, the study will advance to Cohort 2.
Cohort 2 (N = 3-6): will receive VCN-01 as a single IV infusion of 1×1013 vp on Day 0 followed by a single dose of 5×107 cells huCART-meso cells on Day 14 via IV infusion. This cohort will be evaluated as follows:
If 0 DLT/3 subjects or 1 DLT/3 subjects occurs, Cohort 2 will be expanded to enroll an additional 3 evaluable subjects. If 0 DLT/6 subjects or 1 DLT/6 subjects occurs, this dose combination will be defined as the recommended phase 2 dose (RP2D).
If 2 DLTs occur at any time, enrollment in this Cohort will be stopped. If less than 6 subjects were infused in Cohort 1 prior to Cohort 2 escalation, an additional 3 evaluable subjects will be infused at the Cohort 1 dose level to further demonstrate safety and to confirm Cohort 1 as the RP2D (with 0 DLT/6 subjects or 1 DLT/6 subjects).
In the event that 2 DLTs occur in Cohort 1, then enrollment in Cohort 1 will be stopped and Cohort -1 will be opened for evaluation. Cohort -1 will evaluate a different sequence of administration for these two investigational products at the same dose level used in Cohort 1.
• Cohort -1 (N = up to 6): will receive a single dose of 5×107 huCART-meso cells via IV infusions on Day 0 followed by VCN-01 as a single infusion of 3.3×1012 vp on Day 10. Up to 6 subjects will be infused in Cohort -1 unless > 1 DLTs are observed at any time.
The Day 0 infusions of the first two subjects in each cohort will be staggered by at least 42 days from the prior subject’s 1st infusion (huCART-meso or VCN-01; depending on the cohort assignment), to allow for the assessment of DLTs and a formal decision regarding cohort progression, expansion, or de-escalation. Subsequent subject infusions within that cohort will be staggered by at least 14 days from the preceding subject’s second infusion. Formal DLT assessments will be performed by the Clinical PI and Sponsor Medical Director in accordance with the definition provided in the protocol.
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
